Corvus Pharmaceuticals
CRVS
61 hedge funds and large institutions have $136M invested in Corvus Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 10 increasing their positions, 16 reducing their positions, and 12 closing their positions.
156% more call options, than puts
Call options by funds: $7.17M | Put options by funds: $2.8M
116% more capital invested
Capital invested by funds: $63.2M → $136M (+$73.2M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
92% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 12
22% more funds holding
Funds holding: 50 → 61 (+11)
4.64% more ownership
Funds ownership: 61.8% → 66.43% (+4.6%)
38% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$11.1M |
| 2 |
VA
VR Adviser
New York
|
+$10.1M |
| 3 |
PVI
Pura Vida Investments
New York
|
+$2.17M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.95M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$6.83M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$4.43M |
| 3 |
O
OrbiMed
New York
|
-$3.28M |
| 4 |
CA
CHI Advisors
New York
|
-$1.64M |
| 5 |
Two Sigma Advisers
New York
|
-$770K |
CRVS Hedge Fund Activity: Q3 2021 in Review
61 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q3 2021, worth a combined $136M — up 116% from $63.2M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new CRVS positions and 12 closed out — a net gain of 11 holders — while 10 added to existing stakes and 16 trimmed.
The largest buyer was Tang Capital Management, opening a new position worth an estimated $11.1M. The largest seller was BVF Inc, cutting an estimated $6.83M.
- 61 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q3 2021, up from 50 in Q2 2021.
- Funds reported $136M of Corvus Pharmaceuticals stock for Q3 2021, up 116% quarter-over-quarter.
- 23 funds opened new Corvus Pharmaceuticals positions in Q3 2021 and 12 closed out, a net change of +11 holders.
- The largest Corvus Pharmaceuticals buyer in Q3 2021 was Tang Capital Management, an estimated $11.1M added.
- The largest Corvus Pharmaceuticals seller in Q3 2021 was BVF Inc, an estimated $6.83M sold.
Based on aggregated 13F filings for Q3 2021.